ABBOTT LABORATORIES
For the period ended Oct 21, 2026. Filed Oct 21, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Oct 21, 2026 · Filed Oct 21, 2026
Contents
EX-99.1 · A Caution Concerning Forward-Looking Statements
A Caution Concerning Forward-Looking Statements
Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2025, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
| Abbott Financial:Michael Comilla, 224-668-1872Tamika McLoughlin, 224-399-5082Randy Blakley, 224-668-0036 | Abbott Media:Karen Twigg May, 224-668-2681Kate Dyer, 224-668-9965 |
|---|
- In 2025, total worldwide sales were $44.328 billion, which included U.S. sales of $17.126 billion and international sales of $27.202 billion, and Abbott’s Structural Heart business received $89 million of compensation payments as part of a multi-year agreement with a competitor. Also in 2025, total worldwide sales for Exact Sciences were $3.247 billion, which included U.S. sales of $3.145 billion and international sales of $102 million.
Condensed Consolidated Statement of Earnings
| 3Q26 · 3Q25 · % Change | ||||||
|---|---|---|---|---|---|---|
| Net Sales | $13,013 | $11,369 | 14.5 | |||
| Cost of products sold, excluding amortization expense | 5,628 | 5,075 | 10.9 | |||
| Amortization of intangible assets | 841 | 420 | n/m | |||
| Research and development | 920 | 766 | 20.1 | |||
| Selling, general, and administrative | 4,266 | 3,051 | 39.8 | |||
| Total Operating Cost and Expenses | 11,655 | 9,312 | 25.2 | |||
| Operating Earnings | 1,358 | 2,057 | (34.0) | |||
| Interest expense, net | 297 | 44 | n/m | |||
| Net foreign exchange (gain) loss | (6) | (17) | n/m | |||
| Other (income) expense, net | (164) | (150) | 9.4 | |||
| Earnings before taxes | 1,231 | 2,180 | (43.5) | |||
| Taxes on Earnings | 311 | 536 | (42.0) | 1) | ||
| Net Earnings | $920 | $1,644 | (44.1) | |||
| Net Earnings excluding Specified Items, as described below | $2,477 | $2,278 | 8.7 | 2) | ||
| Diluted Earnings per Common Share | $0.53 | $0.94 | (43.6) | |||
| Diluted Earnings per Common Share, excluding Specified Items, as described below | $1.42 | $1.30 | 9.2 | 2) | ||
| Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options | 1,738 | 1,749 | ||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.